CSL Seqirus welcomes the federal government’s announcement highlighting the creation of a new agency, Health Emergency Readiness Canada (HERC), ensuring that Canada is prepared for future health emergencies. As a global leader in influenza protection and champion of pandemic preparedness, CSL Seqirus shares a commitment with government at all levels to help protect Canadians.
The creation of this new agency aligns with similar initiatives from Canada’s G7 peers, including the United States’ Biomedical Advanced Research and Development Authority (BARDA) and the EU’s Health Emergency Preparedness and Response Authority (HERA). In recent months, CSL Seqirus has been selected by both BARDA and HERA to support their pre-pandemic vaccine procurement, demonstrating the company’s commitment to global pandemic preparedness.
For years, CSL Seqirus has engaged with decision-makers in Canada to underscore the importance of pandemic preparedness and to demonstrate how it embraces preparedness as a critical part of public health protection. We are proud to be one of Canada’s suppliers of pandemic influenza vaccines.
“CSL Seqirus is pleased to hear the government is undertaking efforts through HERC to respond to future health emergencies. We look forward to working with the federal government and this new agency to advance emergency readiness in Canada,” said Gillian Stafford, CSL Seqirus Country Head Commercial Operations, Canada.
CSL Seqirus invests approximately $130 million globally each year to advance its promising research and development pipeline. This ongoing commitment to R&D makes a difference and contributes to its ability to help governments prepare for health emergencies. The company is proud of its continued research investments in Canada, which to date accounts for over $10.5 million in R&D funding domestically.
As concerns surrounding highly pathogenic avian influenza (HPAI) grow, CSL Seqirus is committed to working with governments across the globe to strengthen preparedness efforts, including its partners in the government of Canada.
About CSL Seqirus
CSL Seqirus is part of CSL (ASX:CSL). As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. With state-of-the-art production facilities in the U.S., the U.K. and Australia, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.
For more information about CSL Seqirus, visit CSL.com.
About CSL
CSL (ASX: CSL) (USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/we-are-csl/vita-original-stories and follow us on x.com/CSL.
For more information about CSL Limited, visit www.CSL.com.
Media Contact
Tiffany Cody
+1 (908) 370-1863
Tiffany.Cody@seqirus.com